Vital signs: colorectal cancer screening test use--United States, 2012
- PMID: 24196665
- PMCID: PMC4585592
Vital signs: colorectal cancer screening test use--United States, 2012
Abstract
Background: Strong evidence exists that screening with fecal occult blood testing (FOBT), sigmoidoscopy, or colonoscopy reduces the number of deaths from colorectal cancer (CRC). The percentage of the population up-to-date with recommended CRC screening increased from 54% in 2002 to 65% in 2010, primarily through increased use of colonoscopy.
Methods: Data from the 2012 Behavioral Risk Factor Surveillance System survey were analyzed to estimate percentages of adults aged 50-75 years who reported CRC screening participation consistent with United States Preventive Services Task Force recommendations.
Results: In 2012, 65.1% of U.S. adults were up-to-date with CRC screening, and 27.7% had never been screened. The proportion of respondents who had never been screened was greater among those without insurance (55.0%) and without a regular care provider (61.0%) than among those with health insurance (24.0%) and a regular care provider (23.5%). Colonoscopy was the most commonly used screening test (61.7%), followed by FOBT (10.4%). Colonoscopy was used by more than 53% of the population in every state. The percentages of blacks and whites up-to-date with CRC screening were equivalent. Compared with whites, a higher percentage of blacks across all income and education levels used FOBT.
Conclusions: Many age-eligible adults did not use any type of CRC screening test as recommended. Organized, population-based approaches might increase CRC screening among those who have never been screened. Promoting both FOBT and colonoscopy as viable screening test options might increase CRC screening rates and reduce health disparities.
Figures
Similar articles
-
Factors Associated with Colorectal Cancer Screening among Mississippi Adults: Findings from the Behavioral Risk Factor Surveillance System.South Med J. 2020 Jul;113(7):360-365. doi: 10.14423/SMJ.0000000000001115. South Med J. 2020. PMID: 32617599
-
Trends in colorectal cancer test use among vulnerable populations in the United States.Cancer Epidemiol Biomarkers Prev. 2011 Aug;20(8):1611-21. doi: 10.1158/1055-9965.EPI-11-0220. Epub 2011 Jun 8. Cancer Epidemiol Biomarkers Prev. 2011. PMID: 21653643 Free PMC article.
-
Vital signs: colorectal cancer screening among adults aged 50-75 years - United States, 2008.MMWR Morb Mortal Wkly Rep. 2010 Jul 9;59(26):808-12. MMWR Morb Mortal Wkly Rep. 2010. PMID: 20613704
-
Evidence for colorectal cancer screening.Best Pract Res Clin Gastroenterol. 2010 Aug;24(4):417-25. doi: 10.1016/j.bpg.2010.06.005. Best Pract Res Clin Gastroenterol. 2010. PMID: 20833346 Review.
-
Screening for Colorectal Cancer: An Updated Systematic Review [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2008 Oct. Report No.: 08-05-05124-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2008 Oct. Report No.: 08-05-05124-EF-1. PMID: 20722162 Free Books & Documents. Review.
Cited by
-
Approaches to developing de novo cancer population models to examine questions about cancer and race in bladder, gastric, and endometrial cancer and multiple myeloma: the Cancer Intervention and Surveillance Modeling Network incubator program.J Natl Cancer Inst Monogr. 2023 Nov 8;2023(62):219-230. doi: 10.1093/jncimonographs/lgad021. J Natl Cancer Inst Monogr. 2023. PMID: 37947329 Free PMC article.
-
Robotic Colonoscopy and Beyond: Insights into Modern Lower Gastrointestinal Endoscopy.Diagnostics (Basel). 2023 Jul 23;13(14):2452. doi: 10.3390/diagnostics13142452. Diagnostics (Basel). 2023. PMID: 37510196 Free PMC article. Review.
-
Neoplasia Diagnosis After Multi-target Stool DNA Is Enhanced Among Lowest Baseline Detectors.Dig Dis Sci. 2023 Sep;68(9):3721-3731. doi: 10.1007/s10620-023-08038-5. Epub 2023 Jul 24. Dig Dis Sci. 2023. PMID: 37486445 Free PMC article.
-
Baseline Features and Reasons for Nonparticipation in the Colonoscopy Versus Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM) Study, a Colorectal Cancer Screening Trial.JAMA Netw Open. 2023 Jul 3;6(7):e2321730. doi: 10.1001/jamanetworkopen.2023.21730. JAMA Netw Open. 2023. PMID: 37432690 Free PMC article. Clinical Trial.
-
False Reassurance From a Stool Test: A Delayed Cancer Diagnosis.Cureus. 2023 Apr 25;15(4):e38107. doi: 10.7759/cureus.38107. eCollection 2023 Apr. Cureus. 2023. PMID: 37252586 Free PMC article.
References
-
- U.S. Cancer Statistics Working Group. United States cancer statistics: 1999–2010 incidence and mortality web-based report. Atlanta, GA: US Department of Health and Human Services, National Cancer Institute, CDC; 2013. Available at http://www.cdc.gov/uscs.
-
- Howlader N, Noone AM, Krapcho M, et al., editors. SEER cancer statistics review, 1975–2010. Bethesda, MD: National Cancer Institute; Available at http://seer.cancer.gov/csr/1975_2010/
-
- U.S. Preventive Services Task Force. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Rockville, MD: U.S. Preventive Services Task Force; 2008. Available at http://www.uspreventiveservicestaskforce.org/uspstf08/colocancer/colors.htm.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
